Cogent Biosciences, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $27.85
- 52-Week Range
- $26.36 – $43.73
- Market Cap
- $4.84B
- P/E (TTM)
- —
- EPS (TTM)
- -2.26
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 10.72
- PEG Ratio
- —
- Return on Equity
- -99.59%
- Return on Assets
- -42.02%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 10.99
- Debt/Equity
- 0.47
- Total Debt
- $244.22M
- Free Cash Flow
- $-191.62M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $4.36B
Market Snapshot
About
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, particularly advanced systemic mastocytosis and other mast cell-related conditions. Headquartered in Waltham, Massachusetts, the company's lead product candidate is bezuclastinib, an oral tyrosine kinase inhibitor designed to inhibit KIT D816V, a mutation found in most patients with systemic mastocytosis. Cogent utilizes a precision medicine approach to identify and treat patients with specific genetic mutations. The company is advancing clinical development programs for both hematologic and solid tumor indications.